Status:

COMPLETED

Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study

Lead Sponsor:

University Hospital, Basel, Switzerland

Conditions:

Healthy

Eligibility:

All Genders

25-65 years

Phase:

EARLY_PHASE1

Brief Summary

The purpose of this study is to characterize the acute psychological, physiological, endocrine, and pharmacokinetic, as well as long-term psychological effects of LSD in humans.

Detailed Description

Lysergic acid diethylamide (LSD) is the prototype hallucinogen used recreationally worldwide. In the 50-70s, LSD was also used to study psychotic-like states in normals ("model psychosis") and in "psy...

Eligibility Criteria

Inclusion

  • Age between 25 and 65 years
  • Understanding of the German language
  • Understanding the procedures and the risks associated with the study
  • Participants must be willing to adhere to the protocol and sign the consent form
  • Participants must be willing to refrain from taking illicit psychoactive substances during the study
  • Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session, as well as during the study day.
  • Participants must be willing not to drive a traffic vehicle within 48 h following LSD administration.
  • Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session.

Exclusion

  • Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (\>150/95 mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder.
  • Current or previous psychotic or major affective disorder
  • Psychotic or major affective disorder in first-degree relatives
  • Relevant prior illicit drug use (except tetrahydrocannabinol (THC)-containing products) more than 10 times or any time within the previous 2 months.
  • Pregnant or nursing women.
  • Participation in another clinical trial (currently or within the last 30 days)
  • Use of medications that may interfere with the effects of the study medications (any psychiatric medications)
  • Insufficient interpersonal relationship/rapport with study physician as judged by the study physician

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2014

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT01878942

Start Date

June 1 2013

End Date

December 1 2014

Last Update

January 21 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Basel

Basel, Canton of Basel-City, Switzerland, 4031